Integra LifeSciences Announces the Release of the Integra(TM) Total Wrist Fusion System
PLAINSBORO, N.J., March 10, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the release of the Integra™ Total Wrist Fusion System, a solution for wrist arthrodesis that is designed to provide fixation of the wrist while decreasing soft tissue irritation. The system provides an optimal balance of compression and stability by combining the Surfix® locking technology and dynamic compression.
The Integra™ Total Wrist Fusion System has received 510k clearance from the United States Food and Drug Administration (FDA) and will be featured at the American Academy of Orthopaedic Surgeons on March 9-13, in New Orleans, Louisiana.
"The Integra™ Total Wrist Fusion System is a significant addition to our family of upper extremity products," said Robert Paltridge, President of Integra Extremity Reconstruction. "It expands our portfolio of products that address severe wrist arthritis, which includes the Universal2™ Total Wrist Implant System, and gives surgeons another treatment option with unique benefits."
The Integra™ Total Wrist Fusion System will be sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity reconstruction, upper extremity reconstruction, tendon protection/augmentation, peripheral nerve repair/protection, and wound repair.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. The company's products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.integra-ls.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Integra™ Total Wrist Fusion System and the Universal2™ Total Wrist Implant System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Integra LifeSciences Holdings Corp
IART-P
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella, Director of Corporate Communications
(609) 936-2389
gsabella@integra-LS.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.